Drug Trial Radar · NCT04413552
INDV-2000 First in Human
Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Jul 6, 2020
Primary completion
Apr 13, 2021
Study completion Apr 13, 2021
Sponsor
- Lead sponsor
- Indivior Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Jun 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single ascending dose (SAD) study conducted to identify the maximum tolerated dose (MTD) of INDV-2000. After completion of the SAD portion of the study and acceptable safety evaluation, a food-interaction, single-dose study under fed and fasted conditions will be conducted.
Conditions
- Opioid Dependence
Interventions
INDV-2000Drug
INDV-2000 will be administered as either powder in solution or powder in capsule, depending on dose administered.
PlaceboDrug
Placebo will be administered as either powder in solution or powder in capsule, depending on dose administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug to end of study participation for each cohort; 11 days in Part 1 and 7 days in Part II, Period 1 (fasted conditions) and 10 days in Part II, Period 2 (fed conditions).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Altasciences Clinical Kansas
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.